fbpx

Weekly Top News – Psoriasis – August 26, 2019

August 26, 2019

Cosentyx (secukinumab) / Novartis
Cosentyx clinical trial estimate: Data from P3 BE RADIANT trial (NCT03536884) for psoriasis in Q2 2020 (Barclays) – Aug 24, 2019 – A subscription to Thomson ONE is required to gain full access to report 67816038; Page no: 1; REPORT TITLE: “NOVN/UCB: One back for the IL-17s? Kind of…”; AUTHOR: Papadakis, Emmanuel, et al; DATE: 08/13/2019

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
NICE’s fast-track catapults Skyrizi into market (PMLive) – Aug 21, 2019 – “NICE has published a final recommendation for AbbVie and Boehringer Ingelheim’s Skyrizi today, completing a fast-track process which will see the new psoriasis treatment gain market access in record time….Accelerates the review process and also cuts the standard 90 day implementation period down to 30 days. This means the NHS across England has a month from today to make preparations for prescribing of Skyrizi to begin….SVB Leerink analyst Geoffrey Porges predicts $3bn in peak sales for AbbVie’s Skyrizi, with its success dependent on how it will fare not just in psoriasis but the other hotly-contested inflammation and immunology indications as well, such as Crohn’s and ulcerative colitis.”

 

Otezla (apremilast) / Celgene
Bristol-Myers Squibb announces agreement between Celgene and Amgen to divest Otezla for $13.4 billion (Businesswire) – Aug 26, 2019 – “Bristol-Myers Squibb Company…announced today that Celgene Corporation…has entered into an agreement with Amgen…under which Amgen would acquire the global rights to OTEZLA® (apremilast) for $13.4 billion in cash….The closing of the acquisition covered by the agreement with Amgen is contingent on Bristol-Myers Squibb and Celgene entering into a consent decree with the Federal Trade Commission (FTC)…’establishing OTEZLA as an important medicine for patients with psoriasis, psoriatic arthritis and Behçet’s Disease’…Bristol-Myers Squibb now expects the pending merger with Celgene to close by the end of 2019.”

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi pricing: Wholesale acquisition cost of $59,000/year for maintenance dosing (UBS) – Aug 24, 2019 – A subscription to Thomson ONE is required to gain full access to report 67836265; Page no: 1; REPORT TITLE: “AbbVie Inc- First read: AbbVie “Upadacitinib approval mostly in-line w/ expectations””; AUTHOR: Jacob, Navin, et al; DATE: 08/16/2019

 

Taltz (ixekizumab) / Eli Lilly
Taltz sales projection: $1.4B in 2019 (Cantor Fitzgerald) – Aug 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67814539; Page no: 1; REPORT TITLE: “Eli Lilly & Co Lly Standing “Taltz” This morning with positive head to head data”; AUTHOR: Research Department, et al; DATE: 08/13/2019

 

Otezla (apremilast) / Celgene
Otezla TRx: 13,093 in second week of August 2019; Otezla NRx: 4,528 in second week of August 2019 (RBC Capital Markets (Canada)) – Aug 20, 2019 – A subscription to Thomson ONE is required to gain full access to report 67794724; Page no: 3; REPORT TITLE: “Noteworthy wkly script trends (HIV, HCV, MS, CGRP, TKI, PCSK9, Otezla): RBC Coverage W/E 8/2 – Wk 5 of 3Q”; AUTHOR: Abrahams, Brian, et al; DATE: 08/09/2019

No Comments

Post a Comment

Comment
Name
Email
Website